• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Lifeward Ltd.

    5/28/25 4:30:24 PM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email
    SD 1 zk2533292.htm SD


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM SD
    SPECIALIZED DISCLOSURE REPORT

    Lifeward Ltd.
    (Exact name of the registrant as specified in its charter)

    State of Israel
    (State or other jurisdiction of incorporation)
    001-36612
    (Commission file number)
     
                                                                     
     200 Donald Lynch Blvd. Marlborough, MA
     (Address of principal executive offices) 
    01752
    (Zip Code)

    Mike Lawless, Chief Financial Officer, telephone: +508.251.1154
    (Name and telephone number, including area code, of the person to contact in connection with this report)

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:
     
    ☒   Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024

    ☐   Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _____________
     

    Section 1 - Conflict Minerals Disclosures
     
    Item 1.01 – Conflict Minerals Disclosure and Report
     
    Introduction

    This Specialized Disclosure Form (“Form SD”) of Lifeward Ltd. (the “Company,” “we,” or “us”) is filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended (the “1934 Act”), for the reporting period from January 1, 2024 to December 31, 2024.
     
    The Rule requires disclosure of certain information when a company manufactures or contracts to manufacture products for which the minerals specified under the Rule are necessary to the functionality or production of those products. The specified minerals are gold, columbite-tantalite (coltan), cassiterite and wolframite, including their derivatives, which are limited to tantalum, tin and tungsten (collectively, the “Conflict Minerals” or “3TG”), that originated in the Democratic Republic of the Congo (“DRC”) and certain adjoining countries (collectively with the DRC, the “Covered Countries”), unless the Secretary of State in the future determines that additional derivatives are financing conflict in the Covered Countries.

    Per the Rule and the instructions to Form SD, the Company is required to conduct in good faith a reasonable country of origin inquiry regarding the Conflict Minerals that is reasonably designed to determine whether any of the Conflict Minerals originated in any of the Covered Countries, or are from “recycled” or “scrap sources” as defined in Form SD.  Following the country of origin inquiry, the Company must exercise due diligence on the source and chain of custody of such Conflict Minerals if the Company knows or has reason to believe that those Conflict Minerals originated in any of the Covered Countries and knows or has reason to believe that they may not be entirely from recycled or scrap sources.

    Conclusion Based on Reasonable Country of Origin Inquiry

    In accordance with the Rule, the Company has concluded in good faith that during the year ended December 31, 2024:


    •
    Certain of the Company’s operations manufactured, or contracted to manufacture, products (the “Covered Products”) for which the Conflict Minerals are necessary to the functionality or production of those products.

    •
    Based on the Company’s good faith reasonable country of origin inquiry regarding the Conflict Minerals that were used in the Company’s Covered Products in 2024, which was designed to determine whether any of the Conflict Minerals contained in the Company’s Covered Products originated in any of the Covered Countries and whether any of the Conflict Minerals contained in the Covered Products are or may be from entirely recycled or scrap sources, the Company has reason to believe the following: (i) the Conflict Minerals contained in its Covered Products may have originated in one or more of the Covered Countries; and (ii) such Conflict Minerals may not be from entirely recycled or scrap sources.

    On the basis of these conclusions, the Company proceeded to exercise due diligence with respect to the source and chain of custody of the Conflict Minerals contained in its Covered Products. The Conflict Minerals Report (the “CMR”) describing the Company’s due diligence efforts is attached as Exhibit 1.01 to this Form SD for the reporting period from January 1, 2024 to December 31, 2024.  In accordance with applicable guidance from the Securities and Exchange Commission, the Company is not required to obtain an independent private sector audit of its CMR for the year ended December 31, 2024.

    Conflict Minerals Disclosure

    A copy of the Company’s CMR is filed as Exhibit 1.01 hereto and is publicly available on the "Charters & Policies" under the “Corporate Governance” page in the “Investor Relations” section of the Company’s website at https://ir.golifeward.com/corporate-governance/charters-and-policies. Information contained on, or that can be accessed through, the Company’s website does not constitute a part of this Form SD or the attached CMR and is not incorporated by reference herein.
     

    Item 1.02 Exhibit
     
    A copy of the Company’s CMR is filed as Exhibit 1.01 to this Form SD.

    Section 2 – Resource Extraction Issuer Disclosure

    Item 2.01    Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 - Exhibits
     
    Item 3.01 – Exhibits
     
    Exhibit 1.01 — Conflict Minerals Report of Lifeward Ltd. for the year ended December 31, 2024, as required by Items 1.01 and 1.02 of this Form SD.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

    Lifeward Ltd.
    (Registrant)

    /s/ Michael Lawless                                                  May 28, 2025
    Name: Michael Lawless                                                 (Date)
    Title: Chief Financial Officer


    Get the next $LFWD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifeward Names Mark Grant as New CEO

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

      5/19/25 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Present at Sidoti Virtual Investor Conference on May 21

      MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Larry Jasinski, Chief Executive Officer, will make a corporate presentation and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May 21-22, 2025. Joining him will be Mike Lawless, Chief Financial Officer. The presentation will begin at 10:00 AM EDT on May 21, 2025 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_5U4M2xfKTV2ItMDBl

      5/19/25 6:00:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Ltd. Reports First Quarter 2025 Financial Results

      U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

      5/15/25 8:00:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Laidlaw initiated coverage on Lifeward with a new price target

      Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

      2/10/25 7:00:44 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Financials

    Live finance-specific insights

    See more
    • Lifeward Ltd. Reports First Quarter 2025 Financial Results

      U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

      5/15/25 8:00:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561International (

      5/7/25 4:30:25 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-3

      2/28/25 8:00:16 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Jasinski Lawrence J sold $2,405 worth of Ordinary Shares (1,909 units at $1.26) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      5/22/25 4:29:09 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Large owner Lind Global Fund Ii Lp sold $1,655,009 worth of Ordinary Shares (573,110 units at $2.89) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      1/8/25 5:20:52 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Richner Randel sold $7,214 worth of Ordinary Shares (4,285 units at $1.68) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 4:08:29 PM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 8:55:09 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      11/27/24 8:03:53 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      11/26/24 7:07:36 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Leadership Updates

    Live Leadership Updates

    See more

    $LFWD
    SEC Filings

    See more
    • Lifeward Names Mark Grant as New CEO

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

      5/19/25 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Announces Appointment of Robert J. Marshall to Its Board of Directors

      MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, announced the Board of Directors has approved the appointment of Robert J. Marshall Jr. as a new director effective November 2, 2024. As part of his duties as a director, Mr. Marshall will serve as Chairman of the Audit Committee. Mr. Marshall has had a long and accomplished finance career in the medical device industry. Currently, Mr. Marshall serves as the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc., a publicly traded radiopharmaceut

      11/7/24 4:05:14 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Dr. Keith E. Tansey, MD, PhD, will be joining its Medical Affairs team as a consultant in the role of Director, Clinical Research. Dr. Tansey's responsibilities will include the development and stewardship of Lifeward's clinical research program, the advancement of key opinion leader opportunities, and iden

      9/10/24 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Ltd. filed SEC Form 8-K: Leadership Update

      8-K - Lifeward Ltd. (0001607962) (Filer)

      6/3/25 6:01:14 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • SEC Form SD filed by Lifeward Ltd.

      SD - Lifeward Ltd. (0001607962) (Filer)

      5/28/25 4:30:24 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Lifeward Ltd. (0001607962) (Filer)

      5/19/25 8:40:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care